Sirdás sisdollui
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Giella
Buot deaivamat
Bajilčálus
Dahkki
Fáddá
Hildobáiki
ISBN/ISSN
Fáddágilkor
Viečča
Aiddostahtton
Ranibizumab versus Bevacizuma...
Čujuhandieđut
Deakstadieđáhus
Sádde šleađgaboasttain
Čálit
Doalvvo čujuhusa
Doalvun: RefWorks
Doalvun: EndNoteWeb
Doalvun: EndNote
Bissovaš liŋka
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Bibliográfalaš dieđut
Váldodahkkit:
Chakravarthy, U
,
Harding, S
,
Rogers, C
,
Downes, S
,
Lotery, A
,
Wordsworth, S
,
Reeves, B
Materiálatiipa:
Journal article
Almmustuhtton:
2012
Oažžasuvvandieđut
Govvádus
Geahča maid
Bargiidšearbma
Geahča maid
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
Dahkki: Chakravarthy, U, et al.
Almmustuhtton: (2012)
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial
Dahkki: Chakravarthy, U, et al.
Almmustuhtton: (2012)
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
Dahkki: Dakin, H, et al.
Almmustuhtton: (2014)
Bevacizumab versus ranibizumab for neovascular age-related macular degeneration:a Meta-analysis
Dahkki: Wen-Jie Wang, et al.
Almmustuhtton: (2015-02-01)
Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
Dahkki: Zhe-Li Liu, et al.
Almmustuhtton: (2013-04-01)